New drug VIS171 tested for lupus, hair loss, and kidney disease

NCT ID NCT06799520

Recruiting now Disease control Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 26 times

Summary

This early-stage trial tests a new drug called VIS171 in 30 adults with lupus, alopecia areata, or a kidney condition linked to the immune system. The main goal is to see if the drug is safe and tolerable when given as a shot under the skin. Participants will be followed for up to a year.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Visterra Investigational Site
RECRUITING

Sofia, 1404, Bulgaria
Visterra Investigational Site
RECRUITING

Chisinau, MD-2025, Moldova
Visterra Investigational Site
RECRUITING

Bucharest, 11658, Romania
Visterra Investigational Site
RECRUITING

Cluj-Napoca, 40006, Romania
Visterra Investigational Site
NOT_YET_RECRUITING

Barcelona, 8035, Spain
Visterra Investigational Site
NOT_YET_RECRUITING

Granada, 18014, Spain

Conditions

Explore the condition pages connected to this study.

ALOPECIA AREATA (AA) IMMUNE-MEDIATED FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)